Genpharmasec Limited (BOM:531592)
India · Delayed Price · Currency is INR 1.070
-0.050 (-4.46%)
At close: Oct 1, 2026
Genpharmasec Financials Overview
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
| Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Revenue Revenue Growth | 1,776 | 1,399 | 337.22 | 304.06 | 255.16 | 273.21 |
Revenue Growth | 337.77% | 314.98% | 10.91% | 19.16% | -6.61% | 28.22% |
Gross Profit Gross Profit Growth | 133.89 | 113.58 | 29.7 | 61.73 | 21.18 | 7.55 |
Operating Income Operating Income Growth | -13.36 | -7.99 | -1.83 | 0.04 | 2.48 | -5.36 |
Net Income Net Income Growth | 6.48 | 16.04 | 15.86 | -1.69 | 11.25 | -2.09 |
Earnings Per Share EPS Growth | - | 0.03 | 0.03 | -0.01 | 0.04 | -0.01 |
EPS Growth | - | 1.12% | - | - | - | - |
| Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Manufacturing & Processing Manufacturing & Processing Growth | 104.09 | 80.62 | - | - | - | - |
Laboratory Testing Laboratory Testing Growth | - | 10.05 | 11.63 | - | - | - |
Pharmaceuticals Pharmaceuticals Growth | 1,640 | 1,309 | 325.59 | 304.06 | 252.83 | 266.11 |
Total Total Growth | 1,776 | 1,399 | 337.22 | 304.06 | 255.16 | 273.21 |
| Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Cash & Investments Cash & Investments Growth | 100.74 | 100.74 | 52.71 | 217.76 | 36.56 | 59.41 |
Total Debt Total Debt Growth | 349.47 | 349.47 | 52.85 | 38.89 | 30.82 | - |
Net Cash (Debt) Net Cash Growth | -248.73 | -248.73 | -0.13 | 178.87 | 5.74 | 59.41 |
Net Cash Growth | - | - | - | 3018.39% | -90.34% | -58.52% |
Net Cash Per Share Net Cash Per Share Growth | - | -0.45 | -0.00 | 0.58 | 0.02 | 0.21 |
| Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Operating Cash Flow Operating Cash Flow Growth | - | -175.52 | 29.51 | -29.46 | -30.6 | -23.44 |
Capital Expenditures CapEx Growth | - | -5.21 | -57.05 | -0.18 | -0.16 | -0.81 |
Free Cash Flow Free Cash Flow Growth | - | -180.73 | -27.54 | -29.64 | -30.76 | -24.25 |
Free Cash Flow Growth | - | - | - | - | - | - |
| Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Gross Margin | 7.54% | 8.12% | 8.81% | 20.30% | 8.30% | 2.77% |
Operating Margin | -0.75% | -0.57% | -0.54% | 0.01% | 0.97% | -1.96% |
Pretax Margin | -0.01% | 0.69% | 6.56% | 0.82% | 1.10% | -1.62% |
Profit Margin | 0.36% | 1.15% | 4.70% | -0.56% | 4.41% | -0.77% |
FCF Margin | - | -12.91% | -8.17% | -9.75% | -12.05% | -8.88% |
| Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Oct '26 Oct 3, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
PE Ratio | 91.45 | 26.93 | 63.60 | - | 76.55 | - |
PS Ratio | 0.33 | 0.31 | 2.99 | 4.06 | 3.38 | 5.57 |